Neonatology
Review
Stem Cells for the Prevention of Neonatal Lung DiseaseO'Reilly M.a, b · Thébaud B.c-eaDepartment of Pediatrics, and bWomen and Children's Health Research Institute, University of Alberta, Edmonton, Alta., cSprott Centre for Stem Cell Research, Ottawa Hospital Research Institute, and dDivision of Neonatology, Department of Pediatrics, and eCHEO Research Institute, Children's Hospital of Eastern Ontario (CHEO), Ottawa, Ont., Canada
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 05, 2015
Issue release date: June 2015
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)
For additional information: https://www.karger.com/NEO
Abstract
Preterm birth affects approximately 11% of all newborns worldwide and is a major risk factor for infant mortality and morbidity. A common complication of preterm birth is the chronic lung disease of prematurity called bronchopulmonary dysplasia (BPD). Due to the lack of a specific treatment for BPD, preterm infants surviving with BPD face a lifelong risk of poor lung health. The therapeutic potential of stem cells in regenerative medicine is being harnessed for many diseases, including BPD. Compelling preclinical data using stem cells to prevent/repair lung damage in animal models of experimental BPD has built the basis for its translation into the clinic in preterm infants. This review highlights the exciting translation from bench to bedside that will hopefully lead in the near future to improved pulmonary outcomes in preterm infants.
© 2015 S. Karger AG, Basel
Related Articles:
References
- Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, Kinney M, Lawn J; Born Too Soon Preterm Birth Action Group: Born too soon: the global epidemiology of 15 million preterm births. Reprod Health 2013;10(suppl 1):S2.
- Johnston KM, Gooch K, Korol E, Vo P, Eyawo O, Bradt P, Levy A: The economic burden of prematurity in Canada. BMC Pediatr 2014;14:93.
- Chapter 12: Societal costs of preterm birth; in Behrman RE, Butler AS (eds): Preterm Birth: Causes, Consequences, and Prevention. Washington, 2007.
- Jobe AH: The new bronchopulmonary dysplasia. Curr Opin Pediatr 2011;23:167-172.
- Smith LJ, van Asperen PP, McKay KO, Selvadurai H, Fitzgerald DA: Reduced exercise capacity in children born very preterm. Pediatrics 2008;122:e287-e293.
- Ralser E, Mueller W, Haberland C, Fink FM, Gutenberger KH, Strobl R, Kiechl-Kohlendorfer U: Rehospitalization in the first 2 years of life in children born preterm. Acta Paediatr 2012;101:e1-e5.
- Narang I, Rosenthal M, Cremonesini D, Silverman M, Bush A: Longitudinal evaluation of airway function 21 years after preterm birth. Am J Respir Crit Care Med 2008;178:74-80.
- Filippone M, Bonetto G, Corradi M, Frigo AC, Baraldi E: Evidence of unexpected oxidative stress in airways of adolescents born very preterm. Eur Respir J 2012;40:1253-1259.
- Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM: Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics 2006;118:108-113.
- Brostrom EB, Thunqvist P, Adenfelt G, Borling E, Katz-Salamon M: Obstructive lung disease in children with mild to severe BPD. Respir Med 2010;104:362-370.
- Wansleeben C, Barkauskas CE, Rock JR, Hogan BL: Stem cells of the adult lung: their development and role in homeostasis, regeneration, and disease. Wiley Interdiscip Rev Dev Biol 2013;2:131-148.
- Collins JJ, Thébaud B: Progenitor cells of the distal lung and their potential role in neonatal lung disease. Birth Defects Res A Clin Mol Teratol 2014;100:217-226.
- O'Reilly M, Thébaud B: Animal models of bronchopulmonary dysplasia. The term rat models. Am J Physiol Lung Cell Mol Physiol 2014;307:L948-L958.
- Berger J, Bhandari V: Animal models of bronchopulmonary dysplasia. The term mouse models. Am J Physiol Lung Cell Mol Physiol 2014;307:L936-L947.
- Yee M, Vitiello PF, Roper JM, Staversky RJ, Wright TW, McGrath-Morrow SA, Maniscalco WM, Finkelstein JN, O'Reilly MA: Type II epithelial cells are critical target for hyperoxia-mediated impairment of postnatal lung development. Am J Physiol Lung Cell Mol Physiol 2006;291:L1101-L1111.
- van Haaften T, Byrne R, Bonnet S, Rochefort GY, Akabutu J, Bouchentouf M, Rey-Parra GJ, Galipeau J, Haromy A, Eaton F, Chen M, Hashimoto K, Abley D, Korbutt G, Archer SL, Thébaud B: Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009;180:1131-1142.
- Irwin D, Helm K, Campbell N, Imamura M, Fagan K, Harral J, Carr M, Young KA, Klemm D, Gebb S, Dempsey EC, West J, Majka S: Neonatal lung side population cells demonstrate endothelial potential and are altered in response to hyperoxia-induced lung simplification. Am J Physiol Lung Cell Mol Physiol 2007;293:L941-L951.
- Balasubramaniam V, Mervis CF, Maxey AM, Markham NE, Abman SH: Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2007;292:L1073-L1084.
- Alphonse RS, Vadivel A, Fung M, Shelley WC, Critser PJ, Ionescu L, O'Reilly M, Ohls RK, McConaghy S, Eaton F, Zhong S, Yoder M, Thébaud B: Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth. Circulation 2014;129:2144-2157.
- Popova AP, Bozyk PD, Bentley JK, Linn MJ, Goldsmith AM, Schumacher RE, Weiner GM, Filbrun AG, Hershenson MB: Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia. Pediatrics 2010;126:e1127-e1133.
- Bozyk PD, Popova AP, Bentley JK, Goldsmith AM, Linn MJ, Weiss DJ, Hershenson MB: Mesenchymal stromal cells from neonatal tracheal aspirates demonstrate a pattern of lung-specific gene expression. Stem Cells Dev 2011;20:1995-2007.
- Borghesi A, Massa M, Campanelli R, Bollani L, Tzialla C, Figar TA, Ferrari G, Bonetti E, Chiesa G, de Silvestri A, Spinillo A, Rosti V, Stronati M: Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2009;180:540-546.
- Baker CD, Ryan SL, Ingram DA, Seedorf GJ, Abman SH, Balasubramaniam V: Endothelial colony-forming cells from preterm infants are increased and more susceptible to hyperoxia. Am J Respir Crit Care Med 2009;180:454-461.
- Baker CD, Balasubramaniam V, Mourani PM, Sontag MK, Black CP, Ryan SL, Abman SH: Cord blood angiogenic progenitor cells are decreased in bronchopulmonary dysplasia. Eur Respir J 2012;40:1516-1522.
- Zhang X, Wang H, Shi Y, Peng W, Zhang S, Zhang W, Xu J, Mei Y, Feng Z: The role of bone marrow-derived mesenchymal stem cells in the prevention of hyperoxia-induced lung injury in newborn mice. Cell Biol Int 2012;36:589-594.
- Waszak P, Alphonse R, Vadivel A, Ionescu L, Eaton F, Thébaud B: Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev 2012;21:2789-2797.
- Tropea KA, Leder E, Aslam M, Lau AN, Raiser DM, Lee JH, Balasubramaniam V, Fredenburgh LE, Mitsialis SA, Kourembanas S, Kim CF: Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012;302:L829-L837.
- Sutsko RP, Young KC, Ribeiro A, Torres E, Rodriguez M, Hehre D, Devia C, McNiece I, Suguihara C: Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury. Pediatr Res 2013;73:46-53.
- Pierro M, Ionescu L, Montemurro T, Vadivel A, Weissmann G, Oudit G, Emery D, Bodiga S, Eaton F, Peault B, Mosca F, Lazzari L, Thébaud B: Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013;68:475-484.
- Hansmann G, Fernandez-Gonzalez A, Aslam M, Vitali SH, Martin T, Mitsialis SA, Kourembanas S: Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ 2012;2:170-181.
- Chang YS, Oh W, Choi SJ, Sung DK, Kim SY, Choi EY, Kang S, Jin HJ, Yang YS, Park WS: Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2009;18:869-886.
- Chang YS, Choi SJ, Sung DK, Kim SY, Oh W, Yang YS, Park WS: Intratracheal transplantation of human umbilical cord blood derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2011;20:1843-1854.
- Chang YS, Choi SJ, Ahn SY, Sung DK, Sung SI, Yoo HS, Oh WI, Park WS: Timing of umbilical cord blood-derived mesenchymal stem cells transplantation determines therapeutic efficacy in neonatal hyperoxic lung injury. PLoS One 2013;8:e52419.
- Balasubramaniam V, Ryan SL, Seedorf GJ, Roth EV, Heumann TR, Yoder MC, Ingram DA, Hogan CJ, Markham NE, Abman SH: Bone marrow-derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice. Am J Physiol Lung Cell Mol Physiol 2010;298:L315-L323.
- Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, Kourembanas S: Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009;180:1122-1130.
- Ahn SY, Chang YS, Kim SY, Sung DK, Kim ES, Rime SY, Yu WJ, Choi SJ, Oh WI, Park WS: Long-term (postnatal day 70) outcome and safety of intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells in neonatal hyperoxic lung injury. Yonsei Med J 2013;54:416-424.
- Vosdoganes P, Lim R, Koulaeva E, Chan ST, Acharya R, Moss TJ, Wallace EM: Human amnion epithelial cells modulate hyperoxia-induced neonatal lung injury in mice. Cytotherapy 2013;22:1337-1349.
- Zhang H, Fang J, Su H, Yang M, Lai W, Mai Y, Wu Y: Bone marrow mesenchymal stem cells attenuate lung inflammation of hyperoxic newborn rats. Pediatr Transplant 2012;16:589-598.
- Zhang H, Fang J, Wu Y, Mai Y, Lai W, Su H: Mesenchymal stem cells protect against neonatal rat hyperoxic lung injury. Expert Opin Biol Ther 2013;13:817-829.
- Hodges RJ, Jenkin G, Hooper SB, Allison B, Lim R, Dickinson H, Miller SL, Vosdoganes P, Wallace EM: Human amnion epithelial cells reduce ventilation-induced preterm lung injury in fetal sheep. Am J Obstet Gynecol 2012;206:448. e448-e415.
- Vosdoganes P, Hodges RJ, Lim R, Westover AJ, Acharya RY, Wallace EM, Moss TJ: Human amnion epithelial cells as a treatment for inflammation-induced fetal lung injury in sheep. Am J Obstet Gynecol 2011;205:156. e126-e133.
- Baker CD, Seedorf GJ, Wisniewski BL, Black CP, Ryan SL, Balasubramaniam V, Abman SH: Endothelial colony-forming cell-conditioned media promotes angiogenesis in vitro and prevents pulmonary hypertension in experimental bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2013;305:L73-L81.
- Spencer ND, Gimble JM, Lopez MJ: Mesenchymal stromal cells: past, present, and future. Vet Surg 2011;40:129-139.
- Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C: Mesenchymal stem cells derived from Wharton's jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther 2013;8:144-155.
- Fung ME, Thébaud B: Stem cell-based therapy for neonatal lung disease: it is in the juice. Pediatr Res 2014;75:2-7.
- Thébaud B, Abman SH: Bronchopulmonary dysplasia - where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care 2007;175:978-985.
- Hodges RJ, Lim R, Jenkin G, Wallace EM: Amnion epithelial cells as a candidate therapy for acute and chronic lung injury. Stem Cells Int 2012;2012:709763.
- Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh WI, Park WS: Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014;164:966-972. e966.
Article / Publication Details
Published online: June 05, 2015
Issue release date: June 2015
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)
For additional information: https://www.karger.com/NEO
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission